The site-sponsor relationship is a multi-faceted one. The need for communication and understanding between the two is prevalent now more than ever.
The global pandemic has changed the way we think about research. Sponsors should consider how the “new normal” will impact sites and current studies as they plan to re-start research.
While the clinical research community is currently being challenged by the COVID-19 pandemic, adaptive and platform study designs may provide much-needed help for sites.
Recent regulations and policies have ushered in the era of mandated single IRB (sIRB) review. Many institutions must now establish policies and processes for working with an external sIRB.
Quantity of open studies isn’t always the best indicator of success. Be sure you ask these questions before taking on that next clinical trial.
In this Q&A, Dr. Luke Gelinas answers attendee questions from his webinar “Evaluating Payment to Participate in Research: Ethical and Regulatory Issues.”
Long activations is a familiar concept in the clinical trial landscape. How can your site improve your study activation timelines?